ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Α' ΠΑΘΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΣΥΝΤΟΜΟ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

Transcript

1 ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Α' ΠΑΘΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΣΥΝΤΟΜΟ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ ONOMA: ΓΚΟΓΚΑ ΕΛΕΝΑ ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ ιεύθυνση: Α Παθολογική Κλινική Πανεπιστημίου Aθηνών Αγίου Θωμά 17, Αθήνα Προσωπική /νση: T.Θ , Αθήνα Τηλέφωνο: , FAX: , ΤΡΕΧΟΥΣΑ ΘΕΣΗ - Αναπληρώτρια Καθηγήτρια Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Πανεπιστημίου Αθηνών ΕΚΠΑΙ ΕΥΣΗ Ιατρική Σχολή Πανεπιστημίου Αθηνών Σεπτέμβριος 1994: Απόκτηση τίτλου ειδικότητας Παθολογίας ιδακτορικό ίπλωμα, Ιατρική Σχολή, Πανεπιστήμιο Αθηνών Μεταπτυχιακές σπουδές στην Παθολογία-Ογκολογία, Υποτροφία ΙΚΥ εξωτερικού Απρίλιος 2000 Τίτλος Ειδικότητας στην Παθολογία-Ογκολογία μετά από εξετάσεις στο ΚΕΣΥ

2 ΑΚΑ ΗΜΑΪΚΕΣ ΘΕΣΕΙΣ Λέκτορας Παθολογίας-Ογκολογίας, Ιατρική Σχολή, Παν/μίου Αθηνών Επίκουρη Καθηγήτρια Παθολογίας-Ογκολογίας, Ιατρική Σχολή, Παν/μίου Αθηνών 2011-σήμερα Αναπληρώτρια Καθηγήτρια Παθολογίας-Ογκολογίας, Ιατρική Σχολή, Παν/μίου Αθηνών ΘΕΣΕΙΣ ΣΕ ΝΟΣΟΚΟΜΕΙΑ Ειδικευόμενη Παθολογίας, Ογκολογική Κλινική Νοσοκομείου Ευαγγελισμός Ειδικευόμενη Παθολογίας, Β Προπ. Παθολογική Κλινική Πανεπιστημίου Αθηνών, Νοσοκομείο Ευαγγελισμός Μemorial Sloan Kettering Cancer Center New York USA (Department of Gynaecologic Oncology and Department of Developmental Chemotherapy) St.George s Ηospital Medical School, Department of Oncology, London, UK Eπιστημονική συνεργάτης Α Παθολογικής Κλινικής Παν/μίου Αθηνών Λέκτορας-Αναπληρώτρια Καθηγήτρια Παθολογίας-Ογκολογίας, Α Παθολογική Κλινική Ιατρικής Σχολής Παν/μίου Αθηνών Eιδικά αντικείμενα: Μελάνωμα, Καρκίνος μαστού ΕΠΙΣΤΗΜΟΝΙΚΗ ΡΑΣΤΗΡΙΟΤΗΤΑ ημοσιεύσεις και Παρουσιάσεις (up to date) 145 επιστημονικές εργασίες σε ιεθνή Ιατρικά Περιοδικά (pubmed) με περισσότερες από 2600 αναφορές (citations) από άλλους συγγραφείς 24 επιστημονικές εργασίες σε Ελληνικά Ιατρικά Περιοδικά 70 Παρουσιάσεις (Abstracts) σε Ελληνικά Συνέδρια (έως 2009) 70 Παρουσιάσεις (Abstracts) σε ιεθνή Συνέδρια (έως 2009)

3 102 Ομιλίες σε Συνέδρια και Μεταπτυχιακά Μαθήματα κατόπιν προσκλήσεως (έως Φεβρουάριο 2010) TIMHTIKEΣ ΙΑΚΡΙΣΕΙΣ ΒΡΑΒΕΙΑ - 10 βραβεία παρουσιάσεων σε συνέδρια - 1 βραβείο από Ευρωπαϊκό Οργανισμό (CORE research funding) - Μέλος επιστημονικής επιτροπής ASCO για 3ετία (Melanoma/skin cancer) MEΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΟΡΓΑΝΩΣΕΩΝ Ελληνικές Ιατρικός Σύλλογος Αθηνών. Ελληνική Μαστολογική Εταιρεία. Εταιρεία Ογκολόγων-Παθολόγων Ελλάδος (ΕΟΠΕ) Ελληνική Εταιρεία Μελέτης Μελανώματος (Γενική Γραμματέας στην 4ετία και ) Ελληνική Εταιρεία Χειρουργών Μαστού ιεθνείς European Society of Medical Oncology American Society of Clinical Oncology Global Melanoma Task force AIM at melanoma (steering committee) TITΛΟΙ / ΘΕΜΑΤΑ ΙΑΛΕΞΕΩΝ/ ΟΜΙΛΙΩΝ ΣΕ ΙΕΘΝΗ ΣΥΝΕ ΡΙΑ (ενδεικτικά) Ημερομηνία Συνέδριο/εκδήλωση Τίτλος/Θέμα 3-4 Νοvember 2012 Beijing International Melanoma Congress Beijing, China Current landscape in the adjuvant treatment of melanoma-predictive markers November nd Congress of the Mediterranean Multidisciplinary Oncology Forum 9-13 November International Melanoma Congress Tampa, Florida September 2011 Perspectives in melanoma XV New York, USA Molecular Biology Markers in the Selection of Patients Can we predict who will respond to interferon? Is HLA a determinant of prognosis or therapeutic response to cytokines, IFN

4 and anti-ctla4 blocking antibodies in melanoma? 7-8 July 2011 Interdisciplinary Global Conference on Developing New Treatments for Melanoma Munich, Germany June th EADO Congress Nantes, France Biomarkers for interferon responsiveness Biomarkers of interferon responsiveness useful in routine TITΛΟΙ / ΘΕΜΑΤΑ ΗΜΟΣΙΕΥΣΕΩΝ ΣΕ ΙΕΘΝΗ ΠΕΡΙΟ ΙΚΑ Τα τελευταία 3 χρόνια ( ) ιεθνή μόνον (pubmed): Replication and Predictive Value of SNPs Associated with Melanoma and Pigmentation Traits in a Southern European Case-Control Study. Stefanaki I, Panagiotou OA, Kodela E, Gogas H, Kypreou KP, Chatzinasiou F, Nikolaou V, Plaka M, Kalfa I, Antoniou C, Ioannidis JP, Evangelou E, Stratigos AJ. PLoS One. 2013;8(2):e IF Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of- Care Chemotherapy in Patients With Advanced Melanoma. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. J Clin Oncol Feb 10;31(5): IF Obesity and risk of malignant melanoma: a meta-analysis of cohort and casecontrol studies. Sergentanis TN, Antoniadis AG, Gogas HJ, Antonopoulos CN, Adami HO, Ekbom A, Petridou ET. Eur J Cancer Feb;49(3): IF The prognostic and predictive value of mrna expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of highrisk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Linardou H, Kalogeras KT, Kronenwett R, Kouvatseas G, Wirtz RM, Zagouri F, Gogas H, Christodoulou C, Koutras AK, Samantas E, Pectasides D, Bafaloukos D, Fountzilas G. Breast Cancer Res Nov 12;14(6):R IF

5 Prognostic significance of RACGAP1 mrna expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Pliarchopoulou K, Kalogeras KT, Kronenwett R, Wirtz RM, Eleftheraki AG, Batistatou A, Bobos M, Soupos N, Polychronidou G, Gogas H, Samantas E, Christodoulou C, Makatsoris T, Pavlidis N, Pectasides D, Fountzilas G. Cancer Chemother Pharmacol Jan;71(1): IF Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study. Panagopoulou P, Gogas H, Dessypris N, Maniadakis N, Fountzilas G, Petridou ET. Eur J Epidemiol Nov;27(11): IF IFN-α in the treatment of melanoma. Tarhini AA, Gogas H, Kirkwood JM. J Immunol Oct 15;189(8): IF A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. Wang E, Zhao Y, Monaco A, Uccellini L, Kirkwood JM, Spyropoulou-Vlachou M, Panelli MC, Marincola FM, Gogas H. PLoS One. 2012;7(7):e IF Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Ascierto PA, Gogas HJ, Grob JJ, Algarra SM, Mohr P, Hansson J, Hauschild A. Crit Rev Oncol Hematol Feb;85(2): IF Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA. PLoS One. 2012;7(6):e IF Improved survival with MEK inhibition in BRAF-mutated melanoma. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. N Engl J Med Jul 12;367(2): Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilas G. Clin Breast Cancer Jun;12(3): IF Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.

6 Markopoulos C, Tzoracoleftherakis E, Koukouras D, Venizelos B, Zobolas V, Misitzis J, Xepapadakis G, Gogas H. J Cancer Res Clin Oncol Sep;138(9): IF Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. J Transl Med Jul 4;10: IF Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D, Papakostas P, Pentheroudakis G, Gogas H, Skarlos P, Samantas E, Bafaloukos D, Kosmidis PA, Koutras A, Yannoukakos D, Konstantopoulou I, Fountzilas G. Breast Cancer Res Treat Jul;134(1): IF Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions. Markopoulos C, Xepapadakis G, Venizelos V, Tsiftsoglou A, Misitzis J, Panoussis D, Antonopoulou Z, Stathoulopoulou M, Zobolas V, Gogas H. Eur J Surg Oncol May;38(5): IF 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, Nevanlinna H, Greco D, Aittomäki K, Blomqvist C, Chang-Claude J, Vrieling A, Flesch-Janys D, Sinn HP, Wang-Gohrke S, Nickels S, Brauch H; GENICA Network, Ko YD, Fischer HP, Schmutzler RK, Meindl A, Bartram CR, Schott S, Engel C, Godwin AK, Weaver J, Pathak HB, Sharma P, Brenner H, Müller H, Arndt V, Stegmaier C, Miron P, Yannoukakos D, Stavropoulou A, Fountzilas G, Gogas HJ, et al. Cancer Res Apr 1;72(7): IF HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P. J Transl Med Jan 12;10: IF Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P, Stathopoulos GP, Karanikiotis C, Pectasides D, Dimopoulos MA, Fountzilas G. Breast Cancer Res Treat Apr;132(2): IF New challenges in endpoints for drug development in advanced melanoma.

7 Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM. Clin Cancer Res Jan 15;18(2): IF Prognostic significance of UBE2C mrna expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilas G. Ann Oncol Jun;23(6): IF Evaluation of self-assessed melanoma growth rate in a Mediterranean patient population. Nikolaou VA, Sypsa V, Gogas H, Polydorou D, Hasapi V, Gagari E, Stratigos A. Melanoma Res Dec;21(6): IF Insulin resistance in relation to melanoma risk. Antoniadis AG, Petridou ET, Antonopoulos CN, Dessypris N, Panagopoulou P, Chamberland JP, Adami HO, Gogas H, Mantzoros CS. Melanoma Res Dec;21(6): IF Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G. Cancer Chemother Pharmacol Feb;69(2): IF Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Nikolaou V, Kang X, Stratigos A, Gogas H, Latorre MC, Gabree M, Plaka M, Njauw CN, Kypreou K, Mirmigi I, Stefanaki I, Tsao H. Br J Dermatol Dec;165(6): IF Severe thrombocytopenia related to trastuzumab infusion. Mantzourani M, Gogas H, Katsandris A, Meletis J. Med Sci Monit Jul;17(7):CS IF Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, Fountzilas G. Breast Cancer Res Treat May;127(1): IF Prognostic significance of autoimmunity during treatment of melanoma with interferon. Krauze MT, Tarhini A, Gogas H, Kirkwood JM. Semin Immunopathol Jul;33(4): IF Melanoma: the radiotherapeutic point of view; review of the current literature.

8 Zygogianni A, Kyrgias G, Kouvaris J, Mystakidou K, Gogas H, Kouloulias V. Rev Recent Clin Trials May;6(2): Methods of detection of circulating melanoma cells: a comparative overview. Nezos A, Msaouel P, Pissimissis N, Lembessis P, Sourla A, Armakolas A, Gogas H, Stratigos AJ, Katsambas AD, Koutsilieris M. Cancer Treat Rev Jun;37(4): IF Advances and trends in dermato-oncology. Dessinioti C, Gogas H, Stratigos AJ. Expert Rev Anticancer Ther Nov;10(11): IF Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM. J Transl Med Nov 3;8: IF Correlation of molecular human leukocyte antigen typing and outcome in highrisk melanoma patients receiving adjuvant interferon. Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, Stratigos A, Markopoulos C, Pectasides D, Spyropoulou-Vlachou M. Cancer Sep 15;116(18): IF Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group. Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G. Clin Breast Cancer Jun;10(3): Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H. Breast Cancer Res. 2010;12(2):R IF Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study. Lasithiotakis K, Economou G, Gogas H, Ioannou C, Perisynakis K, Filis D, Kastana O, Bafaloukos D, Decatris M, Catodritis N, Frangia K, Papadakis G, Magarakis M, Tsoutsos D, Chrysos E, Chalkiadakis G, Zoras O. Oncol Rep Apr;23(4):